BRAIN AG: New Chairman of the Management Board – Adriaan Moelker takes over from Dr Jürgen Eck
- Adriaan Moelker will act as future CEO to further promote and accelerate profitable commercialisation of the BRAIN Group’s product base
- Dr Jürgen Eck will remain available to the company in an advisory capacity
- Chairman of the Supervisory Board Dr Georg Kellinghusen: “Adriaan Moelker will give important impetus to the next expansion phase of our company.”
Change at the top of the Management Board of BRAIN AG: The company announces, that the Supervisory Board appointed Adriaan (Aryan) Moelker to the Management Board with effect from 1 February 2020 and appointed him as the future Chairman of the Board (CEO). Dr Jürgen Eck, co-founder of BRAIN, Chief Technology Officer (CTO) for around 26 years as well as CEO since 1 August 2015, will resign from the Management Board at the end of this year and will leave the company by mutual agreement. Dr Eck will remain available to BRAIN as a consultant, in particular for the innovation pipeline.
Adriaan Moelker is currently Divisional President for Image Transfer Solutions and a member of the Flint Group Executive Management Team. He has held this position for six years, during which time he has made significant progress in terms of innovation and revenue. Previously, he was CEO of AB Enzymes GmbH in Darmstadt for nine years, during which time he also directed the company towards expansion. Because of this, as well as previous executive positions at Genencor (now DuPont) and marketing positions at DSM, Moelker has more than 20 years of professional experience in industrial biotechnology, where he developed a passion for customer-focused innovation. Moelker is native Dutch with a degree from Nyenrode Business University. He has been working and living with his family in the Frankfurt area for 14 years.
Dr Georg Kellinghusen, Chairman of the Supervisory Board: “Following the successful IPO in 2016 and the successful expansion of the business, BRAIN is now focusing on the consistent commercialisation of its product and project base. The Supervisory Board is convinced that Adriaan Moelker will give important impetus to the next expansion phase of our company. I would like to thank Dr Jürgen Eck for his successful work as CEO over the past four years. His outstanding accomplishments for BRAIN, which he co-founded and has significantly shaped for more than 25 years as CTO and CEO with his innovative power, cannot be appreciated highly enough. He is handing over BRAIN as a successful company that will continue its strong growth course.”
Dr Jürgen Eck:“I am proud of what we have achieved over the past 26 years. The technologies and innovative power to develop new but sustainable products and production processes serve a global megatrend. I would like to thank everyone who has worked and continues to work for BRAIN for their contribution and commitment. I wish my colleagues every success in the further growth of BRAIN as an innovative company in industrial biotechnology.”
Adriaan Moelker, designated Chairman of the Management Board (CEO): “BRAIN is a well-known and highly respected institution in the field of industrial biotechnology. The company’s competencies are as unquestionable as its growth potential. I am looking forward to strengthening BRAIN’s growth course on the basis of the two core segments BioIndustrial and BioScience at this important time for the company. For me personally, this task is taking me back to biotechnology and thus to the industry in which I really feel at home.”
About BRAIN
BRAIN Biotech AG is a leading European supplier of bio-based products and solutions such as enzymes and proteins, microbial production strains, natural compounds and biotechnological solutions for more sustainable industrial processes. The company focuses on the fields of nutrition, health and environment.
BRAIN Biotech AG is the parent company of the international BRAIN Biotech Group. The Group's business activities are divided into three segments: The BioProducts segment comprises the product business with specialty enzymes and other proteins, for which the Group operates fermentation facilities in the United Kingdom and production facilities in continental Europe and the United States. The BioScience segment offers research-intensive custom solutions based on enzyme technology, strain development, bioprocess development and natural product screening. The BioIncubator segment conducts its own R&D projects or those initiated with partners with high value-added potential. A particularly promising incubator project is the development of the Company's own CRISPR-based gene editing technology platform, which is currently being established and expanded by Akribion Genomics (in foundation planning).
Through its own R&D activities, BRAIN Biotech Group is continuously expanding its product portfolio in the field of specialty enzymes and small molecules. The latter are the starting point for screenings, e.g. for novel drug candidates for pharmaceutical applications.
BRAIN Biotech AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since February 9, 2016 (ticker symbol: BNN; securities identification number: ISIN DE0005203947 / WKN 520394). The company employs approximately 330 people and generated revenues of EUR 55,3 million in the fiscal year 2022/23.
For more information, please visit: https://www.brain-biotech.com, LinkedIn, Threads and YouTube.
Disclaimer
This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management. Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance of and future developments at BRAIN Biotech AG and the BRAIN Biotech Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors. BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements.